Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review
Cellular therapies, deemed live medicine, have brought a wave of new generation biological therapies to treat previously untreatable diseases such as cancers and degenerative diseases like osteoarthritis. These cellular therapies have gained significant recognition in clinical research. The area has...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2022/9589600 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564482786721792 |
|---|---|
| author | Kiran Shah Nirali Shah Fatameh Ghassemi Carolyn Ly Teena George Carla Lutz Huseyin Sumer |
| author_facet | Kiran Shah Nirali Shah Fatameh Ghassemi Carolyn Ly Teena George Carla Lutz Huseyin Sumer |
| author_sort | Kiran Shah |
| collection | DOAJ |
| description | Cellular therapies, deemed live medicine, have brought a wave of new generation biological therapies to treat previously untreatable diseases such as cancers and degenerative diseases like osteoarthritis. These cellular therapies have gained significant recognition in clinical research. The area has been further strengthened with the approval of Chimeric Antigen Receptor added on T cells (CAR-T) therapies by the regulatory authorities USA’s Food and Drugs Administration (FDA), European Medical Agency (EMA), the Australian Therapeutic Goods Administration (TGA), and in many countries in 2017 to treat hematological cancers. Another milestone was achieved when allogeneic Mesenchymal Stem Cell- (MSC-) based therapy was approved by the EMA to treat Chrohn’s disease in 2018. Allogeneic donor-derived MSC therapies in particular hold great promise and real hope because of their ‘off-the shelf’ availability and accessibility for patients in need of urgent treatment. So far, thousands of clinical trials have explored the safety and efficacy of both autologous and allogeneic cell therapies, deeming them safe, however with varying degrees of efficacy. In the current pandemic, clinical trials have begun in many parts of the world to treat severe cases of COVID with MSCs. However, the risk of tissue rejection and the development of undesirable effects due to alloreactivity of allogeneic cells are currently not adequately addressed. Therefore, this warrants careful investigation and detailed reporting of such events by clinical researchers. This review aims at discussing the current landscape of approved allogeneic MSCs along with a few other cellular therapies. We explore any possible reactivity reported to inform the readers of any safety concern and on the efficacy of such therapies. |
| format | Article |
| id | doaj-art-7c6014ecc8fc436aa49ff8f5de706601 |
| institution | Kabale University |
| issn | 1687-9678 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-7c6014ecc8fc436aa49ff8f5de7066012025-02-03T01:10:58ZengWileyStem Cells International1687-96782022-01-01202210.1155/2022/9589600Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise ReviewKiran Shah0Nirali Shah1Fatameh Ghassemi2Carolyn Ly3Teena George4Carla Lutz5Huseyin Sumer6Magellan Stem Cells P/LMagellan Stem Cells P/LMagellan Stem Cells P/LMagellan Stem Cells P/LMagellan Stem Cells P/LMagellan Stem Cells P/LDepartment of Chemistry and BiotechnologyCellular therapies, deemed live medicine, have brought a wave of new generation biological therapies to treat previously untreatable diseases such as cancers and degenerative diseases like osteoarthritis. These cellular therapies have gained significant recognition in clinical research. The area has been further strengthened with the approval of Chimeric Antigen Receptor added on T cells (CAR-T) therapies by the regulatory authorities USA’s Food and Drugs Administration (FDA), European Medical Agency (EMA), the Australian Therapeutic Goods Administration (TGA), and in many countries in 2017 to treat hematological cancers. Another milestone was achieved when allogeneic Mesenchymal Stem Cell- (MSC-) based therapy was approved by the EMA to treat Chrohn’s disease in 2018. Allogeneic donor-derived MSC therapies in particular hold great promise and real hope because of their ‘off-the shelf’ availability and accessibility for patients in need of urgent treatment. So far, thousands of clinical trials have explored the safety and efficacy of both autologous and allogeneic cell therapies, deeming them safe, however with varying degrees of efficacy. In the current pandemic, clinical trials have begun in many parts of the world to treat severe cases of COVID with MSCs. However, the risk of tissue rejection and the development of undesirable effects due to alloreactivity of allogeneic cells are currently not adequately addressed. Therefore, this warrants careful investigation and detailed reporting of such events by clinical researchers. This review aims at discussing the current landscape of approved allogeneic MSCs along with a few other cellular therapies. We explore any possible reactivity reported to inform the readers of any safety concern and on the efficacy of such therapies.http://dx.doi.org/10.1155/2022/9589600 |
| spellingShingle | Kiran Shah Nirali Shah Fatameh Ghassemi Carolyn Ly Teena George Carla Lutz Huseyin Sumer Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review Stem Cells International |
| title | Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review |
| title_full | Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review |
| title_fullStr | Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review |
| title_full_unstemmed | Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review |
| title_short | Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review |
| title_sort | alloreactivity of allogeneic mesenchymal stem stromal cells and other cellular therapies a concise review |
| url | http://dx.doi.org/10.1155/2022/9589600 |
| work_keys_str_mv | AT kiranshah alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview AT niralishah alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview AT fatamehghassemi alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview AT carolynly alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview AT teenageorge alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview AT carlalutz alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview AT huseyinsumer alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview |